<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medalphabet-674</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Уровень тяжелых цепей нейрофиламентов, амилоидов 1-40 и 1-42 в спинномозговой жидкости пациентов с оптикомиелитом и рассеянным склерозом</article-title><trans-title-group xml:lang="en"><trans-title>Level of heavy chains of neurofilaments, amyloids 1-40 and 1-42 in cerebrospinal fluid of patients with opticomyelitis and multiple sclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воробьева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorobyova</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симанив</surname><given-names>Т. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Simaniv</surname><given-names>T. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полехина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Polekhina</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Журавлева</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhuravlyova</surname><given-names>M. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захарова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakharova</surname><given-names>M. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуляева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gulyaeva</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фоминых</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fominykh</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зигангирова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zigangirova</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre of Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН «Институт высшей нервной деятельности и нейрофизиологии» РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Higher Nervous Activity and Neurophysiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУН «Институт высшей нервной деятельности и нейрофизиологии» РАН; ГБУЗ «Городская клиническая больница имени В. М. Буянова» Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Higher Nervous Activity and Neurophysiology; City Clinical Hospital n.a. V. M. Buyanov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н. Ф. Гамалеи» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Centre for Epidemiology and Microbiology n.a. honorary academician N. F. Gamalei</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>06</month><year>2018</year></pub-date><volume>2</volume><issue>17</issue><issue-title>Неврология и психиатрия</issue-title><fpage>33</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Воробьева А.А., Симанив Т.О., Полехина Н.В., Журавлева М.Е., Захарова М.Н., Гуляева Н.В., Фоминых В.В., Зигангирова Н.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Воробьева А.А., Симанив Т.О., Полехина Н.В., Журавлева М.Е., Захарова М.Н., Гуляева Н.В., Фоминых В.В., Зигангирова Н.А.</copyright-holder><copyright-holder xml:lang="en">Vorobyova A.A., Simaniv T.O., Polekhina N.V., Zhuravlyova M.E., Zakharova M.N., Gulyaeva N.V., Fominykh V.V., Zigangirova N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/674">https://www.med-alphabet.com/jour/article/view/674</self-uri><abstract><p>Оптикомиелит (ОМ) может приводить к выраженной стойкой инвалидизации за короткий период заболевания. Стойкий неврологический дефицит при демиелинизирующих заболеваниях обусловлен нейродегенеративными изменениями, которые происходят как в самом начале заболевания, так и вторично в то время, когда миелин уже поврежден. Согласно проведенным ранее исследованиям для нейродегенеративного процесса характерно изменение активности ферментов и, как следствие, формирование b-амилоида из мембранного белка предшественника амилоида. Целью исследования было оценить по таким маркерам нейродегенеративного процесса, как b-амилоиды 1-40 и 1-42, отличен ли процесс нейродегенерации при ОМ от РС. Уровень b-амилоидов 1-40 и 1-42 был определен в спинномозговой жидкости методом твердофазного ИФА в следующих группах пациентов: ремиттирующий рассеянный склероз (n = 52), оптикомиелит (n = 5, только случаи, в которых были выявлены антитела к аквапорину - 4) и контрольная группа (n = 26). По уровню b-амилоидов 1-40 и 1-42 было показано отличие группы РС в период обострения от РС в период ремиссии и контрольной группы. При ОМ уровень b-амилоида 1-42 был ниже, чем в группе РС ((Ремиссия». От группы РС ((Обострение» группа ОМ не отличалась. Нами не было выявлено отличий между группами РС и ОМ, которые не могли бы быть объяснены клиническими характеристиками групп.</p></abstract><trans-abstract xml:lang="en"><p>Neuromyelitis optica (NMO) can lead to persistent disability in a short period of time. Persistent neurological deficit in demyelinating disorders is determined by neurodegeneration. As has been shown earlier neurodegeneration is characterized by changes in enzymes activity and shifts in b- amyloid levels. The aim of our study was try to check are there any difference in neurodegeneration of NMO and Multiple Sclerosis (MS) according to b-amyloid 1-40 and 1-42 levels in cerebrospinal fluid. Method. B-amyloids 1-40 and 1-42 were measured by an enzyme-linked immunosorbent assay in patients with MS (n = 52), NMO (n = 5) and control group (n = 26). Results. There was not any difference between NMO and MS (exacerbation). Level of b-amyloid 1-42 was higher in MS remission group than in NMO, but the same difference was detected between remission and exacerbation MS groups.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нейрофиламенты</kwd><kwd>амилоид</kwd><kwd>нейродегенерация</kwd><kwd>демиелинизирующие заболевания</kwd><kwd>оптикомиелит</kwd><kwd>рассеянный склероз</kwd><kwd>цереброспинальная жидкость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neurofilament</kwd><kwd>amyloid</kwd><kwd>neurodegeneration</kwd><kwd>demyelinating diseases</kwd><kwd>neuromyelitis optica</kwd><kwd>multiple sclerosis</kwd><kwd>cerebrospinal fluid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk D. M., Lennon V. A., Pittock S. J. et al. Revised diagnostic criteria for neuromyelitis optica // Neurology.- 2006.- Vol. 66.- Р. 1485-1489.</mixed-citation><mixed-citation xml:lang="en">Wingerchuk D. M., Lennon V. A., Pittock S. J. et al. Revised diagnostic criteria for neuromyelitis optica // Neurology.- 2006.- Vol. 66.- Р. 1485-1489.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk D. M., Banwell B., Bennett J.L et. al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. // Neurology. - 2015, Vol. 85 (2), p. 177-189.</mixed-citation><mixed-citation xml:lang="en">Wingerchuk D. M., Banwell B., Bennett J.L et. al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. // Neurology. - 2015, Vol. 85 (2), p. 177-189.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders // Journal of the Neurological Sciences 2011.- Vol. 311 - P. 69-77.</mixed-citation><mixed-citation xml:lang="en">Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders // Journal of the Neurological Sciences 2011.- Vol. 311 - P. 69-77.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Frischer J. M., Bramow S., Dal-Bianco A., et.al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. // Brain. 2009.- Vol. 132.- P. 1175-1189.</mixed-citation><mixed-citation xml:lang="en">Frischer J. M., Bramow S., Dal-Bianco A., et.al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. // Brain. 2009.- Vol. 132.- P. 1175-1189.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bjartmar C., Kinkel R. P., Kidd G. et.al. Axonal loss in normal-appearing white matter in a patient with acute MS. // Neurology. 2001.- Vol. 57 (7).- P. 1248-1252.</mixed-citation><mixed-citation xml:lang="en">Bjartmar C., Kinkel R. P., Kidd G. et.al. Axonal loss in normal-appearing white matter in a patient with acute MS. // Neurology. 2001.- Vol. 57 (7).- P. 1248-1252.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">De Stefano N., Matthews P.M., Fu L. et. al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. // Brain. 1998.- Vol. 121 (8).- P. 1469-77.</mixed-citation><mixed-citation xml:lang="en">De Stefano N., Matthews P.M., Fu L. et. al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. // Brain. 1998.- Vol. 121 (8).- P. 1469-77.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Valis M., Talab R., Stourac P. et. al. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. // Neuro Endocrinol Lett. 2008.-Vol. 29 (6).- P. 971-976.</mixed-citation><mixed-citation xml:lang="en">Valis M., Talab R., Stourac P. et. al. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. // Neuro Endocrinol Lett. 2008.-Vol. 29 (6).- P. 971-976.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang K., Hein N., Eckert K. et. al. Regulation of the MAD 1 promoter by G-CSF. // Nucleic Acids Res. 2008.- Vol. 36 (5).- P. 1517-1131</mixed-citation><mixed-citation xml:lang="en">Jiang K., Hein N., Eckert K. et. al. Regulation of the MAD 1 promoter by G-CSF. // Nucleic Acids Res. 2008.- Vol. 36 (5).- P. 1517-1131</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sladkova V., Mares J., Lubenova B. et. al. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. // Neurol Res. 2011.- Vol. 33 (4).- P. 415-420.</mixed-citation><mixed-citation xml:lang="en">Sladkova V., Mares J., Lubenova B. et. al. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. // Neurol Res. 2011.- Vol. 33 (4).- P. 415-420.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lennon V., Wingerchuk D., Kryzer T. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis // Lancet. - 2004.- Vol. 364.- Р. 2106-2112.</mixed-citation><mixed-citation xml:lang="en">Lennon V., Wingerchuk D., Kryzer T. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis // Lancet. - 2004.- Vol. 364.- Р. 2106-2112.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk D.M., Lennon V. A., Lucchinetti C. F. et. al. The spectrum of neuromyelitis optica // Lancet Neurol.-2007.- Vol. 6.-P. 805-15.</mixed-citation><mixed-citation xml:lang="en">Wingerchuk D.M., Lennon V. A., Lucchinetti C. F. et. al. The spectrum of neuromyelitis optica // Lancet Neurol.-2007.- Vol. 6.-P. 805-15.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
